Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Citi
Farmers Insurance
McKesson
Fuji
Argus Health
Baxter
Mallinckrodt
Merck

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR XTANDI

« Back to Dashboard

Clinical Trials for Xtandi

Trial ID Title Status Sponsor Phase Summary
NCT00510718 A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer Active, not recruiting Medivation, Inc. Phase 1 This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer. Additional patients will be enrolled in expanded cohorts at doses determined to be tolerable. Patients who tolerate the drug and do not progress will be allowed to continue to look for PSA response.
NCT01302041 A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy Active, not recruiting Medivation, Inc. Phase 2 To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer.
NCT01302041 A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy Active, not recruiting Astellas Pharma Inc Phase 2 To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer.
NCT01534052 A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 Active, not recruiting Medivation, Inc. Phase 2 A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.
NCT01534052 A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 Active, not recruiting Astellas Pharma Inc Phase 2 A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.
NCT01597193 Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer Active, not recruiting Astellas Pharma Inc Phase 1 The purpose of this study is to determine the safety, tolerability and pharmacokinetics of enzalutamide alone and in combination with anastrozole, or exemestane, or fulvestrant in patients with incurable breast cancer.
NCT01597193 Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer Active, not recruiting Medivation is now a wholly owned subsidiary of Pfizer Inc. Phase 1 The purpose of this study is to determine the safety, tolerability and pharmacokinetics of enzalutamide alone and in combination with anastrozole, or exemestane, or fulvestrant in patients with incurable breast cancer.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Xtandi

Condition Name

Condition Name for Xtandi
Intervention Trials
Prostate Cancer 27
Stage IV Prostate Cancer 13
Hormone-Resistant Prostate Cancer 8
Recurrent Prostate Carcinoma 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Xtandi
Intervention Trials
Prostatic Neoplasms 77
Adenocarcinoma 13
Carcinoma 10
Breast Neoplasms 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Xtandi

Trials by Country

Trials by Country for Xtandi
Location Trials
United States 314
Canada 40
United Kingdom 32
Spain 29
France 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Xtandi
Location Trials
California 22
New York 20
Texas 19
Maryland 16
Michigan 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Xtandi

Clinical Trial Phase

Clinical Trial Phase for Xtandi
Clinical Trial Phase Trials
Phase 4 8
Phase 3 9
Phase 2/Phase 3 1
[disabled in preview] 72
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Xtandi
Clinical Trial Phase Trials
Recruiting 52
Active, not recruiting 20
Not yet recruiting 12
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Xtandi

Sponsor Name

Sponsor Name for Xtandi
Sponsor Trials
Medivation, Inc. 40
Astellas Pharma Inc 24
National Cancer Institute (NCI) 17
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Xtandi
Sponsor Trials
Industry 101
Other 72
NIH 17
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Farmers Insurance
Chubb
Queensland Health
QuintilesIMS
Express Scripts
Moodys
Fuji
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.